Tag: Multimodal serotonergic antidepressant

  • Vortioxetine

    Multimodal serotonergic antidepressant

    A multimodal serotonergic antidepressant (Trintellix) FDA-approved 2013 with documented cognitive benefits in addition to mood effects.

    Abstract

    Vortioxetine (Trintellix, Brintellix; CAS 508233-74-7; molecular formula C18H22N2S; molecular weight 298.45) is a multimodal serotonergic antidepressant developed by Lundbeck and Takeda and approved by the FDA in 2013 for major depressive disorder. Mechanism includes serotonin reuptake inhibition (SERT), 5-HT3 antagonism, 5-HT7 antagonism, 5-HT1A agonism, 5-HT1B partial agonism, and 5-HT1D antagonism. The combination produces a clinical profile with antidepressant efficacy plus documented improvements in cognitive function (executive function, processing speed) that are distinct from typical SSRI cognitive profiles. Generally well tolerated.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.